Pulmonary Arterial Hypertension (PAH) Drugs Global Market 2022: Sector to Reach $9.4 Billion by 2027 at a CAGR of 5.29%

DUBLIN, Feb. 3, 2023 /PRNewswire/ -- The "Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

The global pulmonary arterial hypertension (PAH) drugs market size reached US$ 6.9 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 9.4 Billion by 2027, exhibiting a CAGR of 5.29% during 2021-2027.

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Pulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs. It causes the artery walls to tighten and narrow down, thereby exerting additional pressure on the heart to pump blood and weakening the muscles.

In adverse cases, it can also compromise the heart's capacity to pump blood, thus eventually causing heart failure. PAH is characterized by shortness of breath, fatigue and swelling in ankles and legs. It is diagnosed through various tests, such as an echocardiogram, computer tomography (CT) scans, chest X-rays and ventilation-perfusion scans.

It is usually treated using various drugs, such as endothelin receptor antagonists (ERAs), vasodilators, calcium channel blockers (CCBs), anticoagulants, diuretics and cardiac glycosides. These drugs can be inhaled, injected or orally administered.

The increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population that is more susceptible to such medical ailments is providing a boost to the market growth.

In line with this, changes in lifestyles, such as excessive alcohol consumption, a lack of physical activity, and unhealthy dietary patterns, have enhanced the risks of hypertension and high blood pressure.

This, along with the development of novel orphan drugs and technologically advanced devices for the treatment of PAH, is favoring the market growth. Other factors, including increasing awareness among the masses regarding the available treatment alternatives for PAH, and improving healthcare infrastructure across the globe, are expected to drive the market further.

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.

Key Questions Answered in This Report:

  • How has the global pulmonary arterial hypertension (PAH) drugs market performed so far and how will it perform in the coming years?

  • What has been the impact of COVID-19 on the global pulmonary arterial hypertension (PAH) drugs market?

  • What are the key regional markets?

  • What is the breakup of the market based on the drug class?

  • What is the breakup of the market based on the route of administration?

  • What is the breakup of the market based on the end user?

  • What are the various stages in the value chain of the industry?

  • What are the key driving factors and challenges in the industry?

  • What is the structure of the global pulmonary arterial hypertension (PAH) drugs market and who are the key players?

  • What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Class
6.1 Endothelin Receptor Antagonists (ERAs)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Vasodilators
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Soluble Guanylate Cyclase (sGC) Stimulators
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Calcium Channel Blockers (CCBs)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Prostacyclin and Prostacyclin Analogs
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Others
6.7.1 Market Trends
6.7.2 Market Forecast

7 Market Breakup by Route of Administration
7.1 Inhalation
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Injectable
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Oral Administration
7.3.1 Market Trends
7.3.2 Market Forecast

8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Actelion Pharmaceuticals Ltd (Johnson & Johnson) Company Overview Product Portfolio
14.3.2 Arena Pharmaceuticals Inc. Company Overview Product Portfolio Financials SWOT Analysis
14.3.3 AstraZeneca PLC Company Overview Product Portfolio Financials SWOT Analysis
14.3.4 Bayer Aktiengesellschaft Company Overview Product Portfolio Financials SWOT Analysis
14.3.5 Daiichi Sankyo Company Limited Company Overview Product Portfolio Financials SWOT Analysis
14.3.6 Gilead Science Inc. Company Overview Product Portfolio Financials SWOT Analysis
14.3.7 GlaxoSmithKline PLC Company Overview Product Portfolio Financials SWOT Analysis
14.3.8 Merck KGaA Company Overview Product Portfolio Financials SWOT Analysis
14.3.9 Novartis International AG Company Overview Product Portfolio
14.3.10 Pfizer Inc. Company Overview Product Portfolio Financials SWOT Analysis
14.3.11 United Therapeutics Corporation Company Overview Product Portfolio Financials SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/ix2yrt

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets 
Laura Wood, Senior Manager 

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630 
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 
Fax (outside U.S.): +353-1-481-1716

Logo: http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg


View original content:https://www.prnewswire.com/news-releases/pulmonary-arterial-hypertension-pah-drugs-global-market-2022-sector-to-reach-9-4-billion-by-2027-at-a-cagr-of-5-29-301738243.html

SOURCE Research and Markets